SANA BIOTECHNOLOGY INC · Data as of 2026-09-08
2026
We have incorporated this HIP technology into a more scalable manufacturing platform with SC451 and expect to file an investigational new drug application (IND) as well as begin a Phase 1/2 clinical trial for this therapy as early as this year.Source filing
2026
Sana expects to generate first-in-human data for SG293 in non-Hodgkin lymphoma as early as this year.Source filing
2027
We intend to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases and expect to file an IND for SG293 as early as 2027.Source filing
Oct 2
Announced upcoming symposium presentation highlighting UP421 clinical data at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 on October 2Source filing